September 29, 2026Stocks·Bullish·biotech
Invivyd reports clinically meaningful, statistically significant topline data from Phase 3 LIBERTY study of VYD2311
Invivyd announced clinically meaningful and statistically significant topline data from its LIBERTY Phase 3 study evaluating the safety and tolerability of VYD2311, of COVID-19 vaccine COMIRNATY, and of VYD2311 co-administered with an mRNA-based COVID-19 vaccine.
Detected & updated continuously · Source: Nebula
Story subjects